Document is current
Any future updates will be listed below
-
Authors
Hoenigl, Martin https://orcid.org/0000-0002-1653-2824
Seidel, Danila
Sprute, Rosanne https://orcid.org/0000-0003-2457-6437
Cunha, Cristina https://orcid.org/0000-0002-6002-5782
Oliverio, Matteo https://orcid.org/0000-0002-7969-2796
Goldman, Gustavo H. https://orcid.org/0000-0002-2986-350X
Ibrahim, Ashraf S. https://orcid.org/0000-0003-3787-8530
Carvalho, Agostinho https://orcid.org/0000-0001-8935-8030
-
Funding
Funding for this research was provided by:
NOVA | Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa (PTDC/SAU-SER/29635/2017, UIDB/50026/2020 and UIDP/50026/2020)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI153356, R01AI063503)
EC | Horizon 2020 Framework Programme (no. 847507)
- License Information
-
More Information
Article History
Received: 18 November 2021
Accepted: 13 June 2022
First Online: 2 August 2022
Competing interests
: M.H. has received funding from the NIH, Astellas Pharma, Pfizer, Gilead Sciences, MSD, F2G, Euroimmun and SCYNEXIS. A.S.I. received funding from Astellas Pharma, Gilead Sciences and Pfizer and owns shares in Vitalex Biosciences, a start-up company that is developing immunotherapies and diagnostics for mucormycosis.
Free to read: This content has been made available to all.
